HLD-0915 has received FDA fast track designation for mCRPC, expediting its development and review process to address unmet medical needs. Halda Therapeutics is conducting a phase 1/2 clinical trial to ...

TRE-515 has received FDA fast track designation for treating PSMA-positive mCRPC, aiming to accelerate its development and availability. The drug is being tested in combination with Pluvicto, a ...

There are self-care strategies that may aid in helping to prevent prostate cancer, the second most common cause of ...

Here’s how to get relief from the nausea, anxiety, pain, and other symptoms of advanced prostate cancer and its treatments. Palliative care can make life more manageable during cancer treatment, but ...